Inositol
What it is
Inositol is a naturally occurring carbohydrate found in plant and animal foods, with particularly high concentrations in wholegrains, citrus fruits, nuts, and legumes. It exists in nine structural forms, of which myo-inositol (MI) and D-chiro-inositol (DCI) are the two most studied in clinical research and the two most commonly found in supplements. The two forms have distinct biological roles and should not be treated as interchangeable, either in interpreting the evidence or in product selection.
Myo-inositol is the most abundant form in human tissues and plays a central role in cellular signalling, particularly in insulin signalling pathways. It acts as a precursor to inositol triphosphate, a second messenger involved in how cells respond to insulin. D-chiro-inositol is present in lower concentrations and is produced from myo-inositol by a tissue-specific enzyme. The ratio of the two forms in tissues and follicular fluid is tightly regulated under normal conditions, and disruption of this ratio, as observed in women with PCOS, is one of the proposed mechanisms underlying insulin resistance in that condition.
Inositol is classified as a B-vitamin-like compound, though it does not meet the formal criteria for a vitamin since the body can synthesise it. Dietary intake is generally adequate in individuals eating a varied diet, and frank inositol deficiency is not a recognised clinical condition in healthy adults. The rationale for supplementation is therefore not deficiency correction but pharmacological modulation of insulin signalling, primarily in conditions characterised by insulin resistance.
Most of the clinical research has been conducted in women with PCOS or women at elevated risk of gestational diabetes. Evidence in men, healthy women without metabolic abnormalities, older adults, or other populations is very limited.
What the evidence shows
The strongest and most generally consistent clinical evidence for myo-inositol is in the prevention of gestational diabetes mellitus (GDM) in high-risk women. Multiple RCTs and several meta-analyses have found that 4g of myo-inositol daily, begun in early pregnancy, substantially reduces the incidence of GDM in women identified as high risk due to obesity, a family history of type 2 diabetes, or prior GDM. The evidence base is reasonably consistent in direction, with effect sizes that are clinically meaningful, though most trials have been conducted in Italy and risk of bias concerns exist across the body of work.
The PCOS evidence is more nuanced. Myo-inositol has a meaningful effect on insulin resistance biomarkers, specifically fasting insulin and HOMA-IR, in women with PCOS, with consistent direction across several RCTs and meta-analyses. The effect on clinical outcomes including menstrual regularity and ovulation is less consistent and depends heavily on the population studied. Fertility outcomes, including pregnancy rate and live birth rate, are not well-supported by placebo-controlled data, and the most recent guideline review for PCOS concluded that the evidence supporting inositol for fertility specifically is limited and inconclusive. Consumer marketing of inositol for fertility extends considerably beyond what the controlled trial evidence supports.
What the evidence does not show
The evidence does not support the claim that myo-inositol is an established fertility treatment in PCOS. While mechanistic and observational data are encouraging, and some trials have shown improvements in ovulation rate, the placebo-controlled evidence for clinical pregnancy rate and live birth rate is modest and not sufficient to support confident recommendation. Current PCOS guidelines do not recommend inositol as a first-line treatment for fertility.
The evidence also does not support treating myo-inositol and D-chiro-inositol as equivalent. High doses of DCI have been associated with impaired oocyte quality in some research, and the ratio of the two forms in follicular fluid matters in a way that makes simple high-dose DCI supplementation potentially counterproductive. Most of the positive evidence uses myo-inositol, alone or at a physiological MI:DCI ratio.
Evidence in healthy women without PCOS, in men, or in populations without insulin resistance is very limited. The case for supplementation in these groups is not currently supported by the trial evidence.
Does low status cause harm?
Frank inositol deficiency is not a recognised clinical condition in adults consuming a normal diet, and there is no established deficiency syndrome comparable to those seen with vitamins and minerals. The relevant question for inositol is not deficiency but whether specific populations with altered inositol metabolism, primarily women with PCOS, have impaired insulin signalling that supplementation can modify. In that context, reduced myo-inositol in follicular fluid and altered MI:DCI ratios in ovarian tissue are associated with worse reproductive outcomes in PCOS, though whether this reflects a cause or a consequence of the underlying condition remains incompletely understood.
Does supplementation prevent disease?
The strongest preventive evidence is for gestational diabetes. In women at high risk for GDM, myo-inositol supplementation begun in the first trimester has been associated with meaningful reductions in GDM incidence across multiple trials and meta-analyses. The effect is not established for the prevention of type 2 diabetes more broadly, or for metabolic disease prevention outside of pregnancy in high-risk populations.
Does it affect biomarkers?
Yes, particularly in women with PCOS. Myo-inositol supplementation consistently reduces fasting insulin and HOMA-IR in PCOS populations across multiple RCTs. Effects on testosterone, LH:FSH ratio, and SHBG are observed in some but not all trials, and the evidence for androgen reduction is less consistent than for insulin-related markers. Improvements in SHBG appear more robust after longer supplementation periods of at least 24 weeks.
Does it help clinical populations?
The clearest clinical application is in two specific populations: women at high risk for gestational diabetes, where the GDM prevention evidence is reasonably strong, and women with PCOS seeking improvement in metabolic markers and menstrual regularity, where the biomarker evidence is moderate and the clinical outcome evidence is more limited. Evidence in other clinical populations is insufficient to draw conclusions.
Does it benefit healthy individuals?
There is no meaningful evidence that myo-inositol supplementation benefits individuals without insulin resistance or related metabolic conditions. In healthy adults with normal insulin sensitivity, the pharmacological rationale for supplementation is weak, and trial evidence in this group is essentially absent.
Individual variation
The evidence for inositol is almost entirely population-specific. Women with PCOS represent the primary studied group across the non-pregnancy literature, and responses within that group vary according to the severity of insulin resistance, body weight, and whether PCOS is primarily androgen-excess-driven or metabolically driven. Leaner women with PCOS and less pronounced insulin resistance show smaller and less consistent metabolic responses to myo-inositol than women with more significant insulin resistance.
Women at high risk for gestational diabetes, those with obesity, a personal or family history of type 2 diabetes, or prior GDM, are the group where the preventive evidence is strongest. The same intervention in women without these risk factors has not been adequately studied.
Postmenopausal women with metabolic syndrome represent a small additional evidence base, a limited number of Italian RCTs have found myo-inositol to have modest effects on metabolic markers in this group, but the evidence is too small to draw firm conclusions.
Men are almost entirely absent from the research base for inositol supplementation. The female-specific focus of the clinical literature is itself a reflection of how the evidence has developed, concentrated around reproductive and obstetric applications.
For women of reproductive age considering inositol for PCOS or fertility purposes, the form ratio matters. A physiological MI:DCI ratio of 40:1, reflecting the natural ratio in follicular fluid, has been proposed as optimal and is used in some trial protocols. Very high doses of DCI relative to myo-inositol may be counterproductive for oocyte quality.
Testing and status assessment
There are no widely available clinical tests for inositol status. The research on follicular fluid MI:DCI ratios is primarily conducted in research settings and is not accessible through standard testing. Serum inositol levels are not routinely measured in clinical practice and their interpretation is not standardised.
The most clinically relevant diagnostic information for guiding inositol supplementation decisions is not an inositol-specific test but an assessment of insulin resistance. HOMA-IR, fasting insulin, and fasting glucose provide a reasonable picture of the metabolic context in which myo-inositol is most likely to produce benefit. In the context of PCOS, hormonal markers including LH, FSH, testosterone, and SHBG characterise the condition being addressed and provide a baseline against which any response can be measured.
Safety and contraindications
Myo-inositol at doses up to 4g per day is generally well tolerated. The most commonly reported adverse effects are mild gastrointestinal symptoms including nausea and diarrhoea, which are typically transient. Across RCTs in both PCOS and gestational diabetes populations, the adverse event profile has been consistently described as favourable and better tolerated than metformin in direct comparison studies. No serious adverse events have been reported in trials at these doses.
D-chiro-inositol at high doses is a more important safety consideration in women seeking to use inositol for reproductive purposes. Research has found that excessive DCI in follicular fluid is associated with impaired oocyte quality, and this has been observed in some trial protocols using high DCI doses. Preparations with a physiological MI:DCI ratio are therefore generally preferred over high-dose DCI products.
Safety data in pregnancy at the doses used in GDM prevention trials (2 to 4g myo-inositol per day) has been reassuring across multiple trials, with no adverse fetal outcomes observed. However, the evidence base is concentrated in the first and second trimesters, and long-term safety data extending into later pregnancy and postpartum is more limited. Women considering inositol during pregnancy should discuss this with their obstetric provider.
There are no established clinically significant drug interactions for myo-inositol. In PCOS management, inositol is sometimes used alongside metformin or combined oral contraceptives; these combinations have been studied in some trials without identified safety concerns, though the additive benefit over either treatment alone is not firmly established.
What can reasonably be concluded
The strongest evidence for inositol is in the prevention of gestational diabetes in high-risk women, where a meaningful and consistent reduction in GDM incidence has been observed across multiple trials. This represents the most clinically defensible application of myo-inositol supplementation.
In PCOS, myo-inositol has a reasonable evidence base for improving insulin resistance biomarkers and modest evidence for improving menstrual regularity and ovulation in some populations. The metabolic benefits are real but more limited than the commercial positioning of inositol implies, and the fertility claims specifically extend well beyond what placebo-controlled trials support. Current PCOS guidelines describe the evidence as limited and inconclusive, which accurately reflects the state of the literature.
Form matters. Myo-inositol has the strongest evidence base. D-chiro-inositol is not interchangeable, and high DCI doses may be counterproductive in reproductive contexts. Where a ratio formulation is used, physiological ratios should be preferred over arbitrary high-DCI products.
In healthy women without insulin resistance, in men, and in other populations without a specific clinical rationale, the evidence base does not support supplementation. Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.